SHOULD YOU AVOID ANY FOODS OR SUPPLEMENTS WITH PARKINSON'S DISEASE?
Welcome to Our Parkinson's Place
I copy news articles pertaining to research, news and information for Parkinson's disease, Dementia, the Brain, Depression and Parkinson's with Dystonia. I also post about Fundraising for Parkinson's disease and events. I try to be up-to-date as possible. I have Parkinson's diseases as well and thought it would be nice to have a place where updated news is in one place. That is why I began this blog.
I am not responsible for it's contents, I am just a copier of information searched on the computer. Please understand the copies are just that, copies and at times, I am unable to enlarge the wording or keep it uniformed as I wish. This is for you to read and to always keep an open mind.
Please discuss this with your doctor, should you have any questions, or concerns. Never do anything without talking to your doctor. I do not make any money from this website. I volunteer my time to help all of us to be informed. Please no advertisers. This is a free site for all.
Saturday, January 3, 2015
|Dr. Donald Cantway|
Steamboat Springs — Retired emergency room physician Dr. Donald Cantway, of Steamboat Springs, is living well with Parkinson’s disease thanks to an exercise regimen that includes the classic style of cross country skiing and the medical marvel of a battery-operated neurostimulator implanted in his brain two years ago.
“The change was just amazing to me,” Cantway said about the surgically implanted electronic stimulator that significantly mitigated the impacts of Parkinson’s, which include tremors, rigid joints, slowed movements and difficulty walking.
Parkinson’s is a result of the degeneration and damage to the dopamine-producing cells in an area of the hypothalamus of the brain called the “substantia negra,” according to Brown University. It is dopamine that enables the coordinated movements of a person’s muscles.
Not coincidentally, cross country skiing is part of Cantway’s exercise regimen.
“Parkinson’s takes away your fine motor movements, and exercises that require big motions help,” Cantway said.
He said the diagonal stride of classic cross country skiing with swinging arm motions is particularly effective for him.
“It’s ideal. The only problem is that if you fall down, it can be hard to get up,” he said.
He and other people living with Parkinson’s in Steamboat Springs also attend regular exercise classes tailored specifically for their needs.
“Exercises designed to improve balance and mobility — those are the things you lose,” Cantway added.
Clinical sociologist Lindarose Berkley told the Steamboat Today in 2013 that 15 people who had been diagnosed with Parkinson’s were attending regular support group meetings.
“I know there are many more people out there. I know of one woman whose husband (has Parkinson’s) and won’t come, but she will,” Berkley said at the time.
For 35 years, Cantway, 72, commuted from his home in Steamboat to a hospital in Laramie, Wyoming, where he worked for a week at a time as an emergency room doctor. He said he preferred practicing that form of medicine in a city where he wasn’t familiar with patients who had been in an emergency. When diagnosed with Parkinson’s six to seven years ago, he had to give up his practice.
“I couldn’t multitask any more, and I was becoming slower in making decisions,” he said.
Deep brain stimulation isn’t appropriate for all patients — some are more suited to treating the reduced dopamine production that leads to Parkinson’s with prescriptions, Cantway said. But he consulted a neurologist in Cheyenne, Wyoming, who encouraged him to undergo deep brain stimulation surgery “sooner than later.”
Like the typical patient, Cantway put it off for five years. And then, the initial surgery resulted in an infection. When that cleared up, Cantway underwent a different form of surgery that was very successful.
Today, he self-regulates the neurotransmitter to meet his needs. Cantway continues to drive his car around Steamboat, walks without shuffling and has no noticeable hand tremors.
And Cantway thrives on exercise.
“I’ve been working out all my life,” he said.
To reach Tom Ross, call 970-871-4205, email tross@SteamboatToday.com or follow him on Twitter @ThomasSRoss1
If you go
What: Benefit for people exercising to manage Parkinson’s disease
When: 10 a.m. to 2 p.m. Jan. 10
Where: Haymaker Nordic Center, 34855 E. U.S Highway 40
Details: For a minimum donation of $50, participants can enjoy a day pass at Haymaker, 30-minute mini lesson, lunch, access to silent auction, voucher for a pass at Steamboat Ski Touring Center, $10 discount on rental gear day of event (reserve ahead of time) and an opportunity to purchase Haymaker season pass at early season rates (day of event only).
For the Parkinson’s support group in Steamboat Springs, call 970-875-1088.
Steamboat Springs has an increasingly active Parkinson’s support group, which includes people who are among the 1.5 million Americans living with the disease and their families and professionals such as exercise therapists, yoga instructors and, yes, ski instructors.
Mark Traum, an employee and instructor at the Steamboat Ski Touring Center, who has been diagnosed with Parkinson’s himself, is helping to organize a Jan. 10 fundraiser at Haymaker Nordic Center including lunch, a mini-lesson, a Haymaker day pass and a voucher for a pass at the Steamboat Ski Touring Center, discounts on rentals on event day and a silent auction, for the minimum donation of $50.
Friday, January 2, 2015
Thursday, 1 January 2015
Wednesday, December 31, 2014
12/30/2014 11:12 PM ET
Aquinox Pharmaceuticals Inc. (AQXP: Quote) has initiated dosing in a phase II clinical trial of AQX-1125 for the treatment of atopic dermatitis.
The trial, dubbed KINSHIP, designed to enroll about 50 adult patients with mild to moderate atopic dermatitis is being conducted at clinical research centers in Canada.
AQXP closed Tuesday's trading 6.46% higher at $7.25.
ARIAD Pharmaceuticals Inc. (ARIA: Quote) has granted Angelini Pharma exclusive rights to commercialize leukemia drug Iclusig in seven Central and Eastern European countries.
The seven countries include Bulgaria, the Czech Republic, Hungary, Poland, Romania, Slovakia and Slovenia. The commercial launches of Iclusig in these Central and Eastern European countries are expected to begin in 2015.
With this distributorship in place, Iclusig will be available to patients with resistant and intolerant Philadelphia-positive leukemias in more than 23 countries in Europe.
Net product revenues from sales of Iclusig were $14.5 million for the quarter ended September 30, 2014, an increase of 22% from the second quarter of 2014.
ARIA closed Tuesday's trading at $6.82, down 1.23%. In after-hours, the stock was up 1.25% at $6.90.
Idera Pharmaceuticals Inc.'s (IDRA: Quote) drug candidate IMO-8400 has been granted orphan drug designation by FDA for the treatment of Waldenström's macroglobulinemia, a type of non-Hodgkin lymphoma.
IMO-8400 is currently under a phase 1/2 clinical trial in patients with Waldenström's macroglobulinemia who have a history of relapse or failure to respond to one or more prior therapies. The company expects final 24-week safety and clinical activity from the trial in the second half of 2015.
IDRA closed Tuesday's trading at $4.36, down 3.00%.
Shares of NephroGenex Inc. (NRX: Quote) were up more than 118 percent in Tuesday's extended trading following successful completion of a thorough QT/QTc (TQT) cardiac safety study on the company's drug candidate Pyridorin.
Pyridorin is under phase III testing in patients with diabetic nephropathy.
A TQT study is a specialized clinical trial designed to assess whether an investigational drug has the potential to prolong the QT interval. Note that a prolonged QT interval increases the risk of sudden cardiac death and arrhythmias.
NRX closed Tuesday's trading at $4.65, down 1.90%. In after-hours, the stock was up 118.28% at $10.15.
NeuroDerm Ltd. (NDRM: Quote) surged more than 193% on Tuesday following encouraging topline results of a phase IIa pharmacokinetic study of its product candidates ND0612H and ND0612L for the treatment of Parkinson's disease.
According to the European Parkinson's Disease Association, people with Parkinson's have reduced levels of dopamine, a chemical messenger in the brain involved in coordinating the nerve cells and muscles which control movement.
Levodopa, which is converted into dopamine in the brain, is considered the gold standard treatment for Parkinson's. However, due to the short half-life of oral Levodopa, patients are required to take multiple doses daily. But steady Levodopa delivery can currently only be achieved after undergoing an invasive surgical procedure whereby a tube is permanently implanted into the duodenum, the upper part of the small intestine.
Given the fact that continuous, subcutaneous delivery of product candidates, ND0612H and ND0612L, led to clinically-significant plasma levodopa levels in the phase IIa study, the company expects the high dose version ND0612H to offer a simple and effective treatment option that will minimize the need for surgical intervention in advanced Parkinson's patients.
NeuroDerm expects to proceed with the clinical development of ND0612H and ND0612L in the United States and the European Union in 2015.
NeuroDerm went public as recently as November 14, 2014 priced at $10 per share. The stock closed Tuesday's trading at $18.14, up 193.53%.
Sucampo Pharmaceuticals Inc.'s (SCMP: Quote) New Drug Submission for AMITIZA for the treatment of chronic idiopathic constipation in adults and opioid induced constipation in adults with chronic non-cancer pain has been accepted for review by Health Canada.
The drug is already available in the U.S., Japan, U.K. and Switzerland, with over nine million prescriptions written in the US alone.
Sucampo has a global license, development, commercialization and supply agreement with Takeda Pharmaceutical Co. Limited for AMITIZA.
SCMP closed Tuesday's trading at $13.89, down 0.29%.
Synthetic Biologics Inc. (SYN: Quote) has initiated a phase 1b clinical trial of its drug candidate SYN-004 for the prevention of Clostridium difficile infection.
The company expects to report topline data from the phase 1b clinical trial and initiate a phase 2 SYN-004 clinical trial during the first quarter of 2015.
SYN closed Tuesday's trading 1.34% down at $1.47.
Tuesday, December 30, 2014
12/30/2014 9:52 AM ET
Clinical-stage pharmaceutical company NeuroDerm Ltd. (NDRM: Quote), which went public in November, announced Tuesday topline results for a mid-stage study for its proprietary liquid levodopa/carbidopa (LD/CD) product candidates as a treatment for Parkinson's disease.
Following the announcement, the company's shares are skyrocketing more than 49 percent in early deals.
The company said the continuous, subcutaneous delivery of the liquid product candidates, ND0612H and ND0612L, led to clinically-significant plasma levodopa levels. The company added that ND0612H, the higher dose version, provided an effective alternative to current treatments that require surgery.
"Maintaining consistent levodopa concentrations has been the most significant hurdle in Parkinson's disease therapy. The results from this study demonstrate that ND0612H can reach high LD plasma levels that, to date, could only be reached and maintained by products that require surgical intervention," said Sheila Oren, NeuroDerm's Vice President of Clinical and Regulatory Affairs.
The phase IIa study was conducted on 16 patients with an advanced form of Parkinson's disease having motor fluctuations that was chronically treated with standard of care oral LD/CD. The primary endpoints of the study were to assess the safety, tolerability and pharmacokinetics (PK) of six dose regimens of ND0612H and ND0612L.
The patients were treated with ND0612L (n=9) or ND0612H (n=7) for eight hours per day, for three consecutive days, with high and low doses of CD, and with adjunct oral entacapone. The LD/CD product candidates are continuously administered subcutaneously through a belt-worn pump.
The trial results showed that patients receiving ND0612H achieved maximum daytime levodopa plasma concentrations of 1,333ng/ml and 1,807ng/ml with oral entacapone added.
Meanwhile, patients receiving ND0612L achieved maximum daytime concentrations of 528ng/ml and 596ng/ml with oral entacapone added.
The company confirmed that all patients completed the study and treatment with ND0612L and ND0612H did not raise safety and tolerability concerns.
Rehovot, Israel-based NeuroDerm focuses on developing drugs for central nervous system (CNS) diseases.
The company noted that it will now proceed with the clinical development of ND0612H and ND0612L in the U.S. and the European Union in 2015, based on the promising mid-stage trial results.
Parkinson's disease is a progressive neurodegenerative illness characterized by reduced dopamine in the brain, resulting in a debilitating decrease in the patient's motor and non-motor functions. Its symptoms, such as trembling in the extremities and face, slowness of movement and impaired balance and coordination, worsen over time and gravely impact the patient's quality of life.
In Tuesday's regular trading session, NDRM is currently trading at $9.23, up $3.05 or 49.35% on a volume of 2.32 million shares. In the past 52-week period, the stock has been trading in a range of $5.67 to $9.45.
Sunday, December 28, 2014
Fatigue can be described as an overwhelming sense of tiredness, a lack of energy and a feeling of exhaustion.
People with Parkinson's can experience fatigue at any time during their condition.
Although many people use the terms fatigue and sleepiness interchangeably, they are considered separate things.
Fatigue can be a physical, mental or an emotional feeling. Anybody can feel fatigued when they are working too hard, or when pressures at work or at home cause stress.
Fatigue can also be a symptom of an illness and it can be difficult to work out what may be causing it.
How can fatigue affect people with Parkinson's?
People with Parkinson's can experience fatigue at any time during their condition, and how it can affect them can change from day to day.
You may feel quite fit and able one day and then too tired to do much the following.
Many people with Parkinson's can also experience problems with sleeping at night, which can often leave you feeling tired and lethargic during the day.
Read more about sleep and night-time problems
If you're depressed, you may experience a range of symptoms, as well as low mood, for long periods of time. This includes fatigue.
You may feel tired, have difficulty sleeping and have a lack of interest in your usual activities. If you have fatigue and are concerned about depression, speak to your GP, specialist or Parkinson's nurse (if you have one).
Read more about depression and Parkinson's
Fatigue may also imitate apathy, which may mean you lose interest in activities that you used to enjoy.
Apathy, like depression, needs to be diagnosed so it can be treated. You may find it helpful to speak to a mental health specialist or counsellor about it.
What can help with fatigue?
There are a number of things you can do to try to avoid fatigue or help reduce it.
- ¥ Try to take short, regular breaks at work. This can be as simple as making a cup of tea, having a chat with a colleague, or sitting back for a few moments with your eyes closed.
- ¥ Divide household tasks so that you do the jobs you can manage more easily.
- ¥ Try to get some regular exercise.
- ¥ Stay in involved with any hobbies and interests you have – boredom can lead to fatigue.
- ¥ Try to eat a healthy, balanced diet. Some people find that regular, healthy snacks help to keep their energy levels up.
- ¥ Pace yourself and understand your limitations.
Although it's natural to associate any health problems with Parkinson's, there may be other causes of fatigue unrelated to your condition.
It's important to discuss any feelings of fatigue with your GP, specialist or Parkinson's nurse.
So it is important to discuss any feelings of fatigue with your GP, specialist or Parkinson's nurse.
Together, you can look at what the cause of your fatigue is and discuss treatment options.
If your feelings of fatigue are related to other Parkinson's symptoms, it may be helped with Parkinson's medication. This will also help you manage your symptoms better, so you have more energy to do things that may otherwise be difficult.
It might be possible to manage fatigue with other, non-Parkinson's medication. We recommend that you discuss this carefully with your GP or specialist. In some cases non-drug treatments, such as cognitive behavioural therapy, may help.
- - See more at: http://www.parkinsons.org.uk/content/fatigue-and-parkinsons#sthash.7iKdp8qx.7XvuuYan.dpuf